<SEC-DOCUMENT>0001646343-17-000008.txt : 20171114
<SEC-HEADER>0001646343-17-000008.hdr.sgml : 20171114
<ACCEPTANCE-DATETIME>20171114162016
ACCESSION NUMBER: 0001646343-17-000008
CONFORMED SUBMISSION TYPE: 13F-HR
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20170930
FILED AS OF DATE: 20171114
DATE AS OF CHANGE: 20171114
EFFECTIVENESS DATE: 20171114
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEXTHERA CAPITAL LP
CENTRAL INDEX KEY: 0001646343
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 13F-HR
SEC ACT: 1934 Act
SEC FILE NUMBER: 028-17280
FILM NUMBER: 171201839
BUSINESS ADDRESS:
STREET 1: 900 THIRD AVENUE
STREET 2: SUITE 1100
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 213-7033
MAIL ADDRESS:
STREET 1: 900 THIRD AVENUE
STREET 2: SUITE 1100
CITY: NEW YORK
STATE: NY
ZIP: 10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>13F-HR
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?>
<edgarSubmission xmlns="http://www.sec.gov/edgar/thirteenffiler" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>13F-HR</submissionType>
<filerInfo>
<liveTestFlag>LIVE</liveTestFlag>
<flags>
<confirmingCopyFlag>false</confirmingCopyFlag>
<returnCopyFlag>true</returnCopyFlag>
<overrideInternetFlag>false</overrideInternetFlag>
</flags>
<filer>
<credentials>
<cik>0001646343</cik>
<ccc>XXXXXXXX</ccc>
</credentials>
</filer>
<periodOfReport>09-30-2017</periodOfReport>
</filerInfo>
</headerData>
<formData>
<coverPage>
<reportCalendarOrQuarter>09-30-2017</reportCalendarOrQuarter>
<filingManager>
<name>NEXTHERA CAPITAL LP</name>
<address>
<com:street1>900 THIRD AVENUE</com:street1>
<com:street2>SUITE 1100</com:street2>
<com:city>NEW YORK</com:city>
<com:stateOrCountry>NY</com:stateOrCountry>
<com:zipCode>10022</com:zipCode>
</address>
</filingManager>
<reportType>13F HOLDINGS REPORT</reportType>
<form13FFileNumber>028-17280</form13FFileNumber>
<provideInfoForInstruction5>N</provideInfoForInstruction5>
</coverPage>
<signatureBlock>
<name>Daniel Malek</name>
<title>Managing Member of the General Partner Phone:</title>
<phone>6462137030</phone>
<signature>Daniel Malek</signature>
<city>New YOrk</city>
<stateOrCountry>NY</stateOrCountry>
<signatureDate>11-14-2017</signatureDate>
</signatureBlock>
<summaryPage>
<otherIncludedManagersCount>0</otherIncludedManagersCount>
<tableEntryTotal>38</tableEntryTotal>
<tableValueTotal>388737</tableValueTotal>
<isConfidentialOmitted>false</isConfidentialOmitted>
</summaryPage>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>INFORMATION TABLE
<SEQUENCE>2
<FILENAME>Q3_2017_13F.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<ns1:informationTable xmlns:ns1="http://www.sec.gov/edgar/document/thirteenf/informationtable">
<ns1:infoTable>
<ns1:nameOfIssuer>Abeona Therapeutics Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>00289Y107</ns1:cusip>
<ns1:value>5115</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>300000</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:putCall>Call</ns1:putCall>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>300000</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Achaogen Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>004449104</ns1:cusip>
<ns1:value>9215</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>577766</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>577766</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Aclaris Therapeutics Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>00461U105</ns1:cusip>
<ns1:value>10745</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>416312</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>416312</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Alexion Pharmaceuticals Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>015351109</ns1:cusip>
<ns1:value>8745</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>62337</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>62337</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Alnylam Pharmaceuticals Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>02043Q107</ns1:cusip>
<ns1:value>9372</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>79772</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>79772</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Array BioPharma Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>04269X105</ns1:cusip>
<ns1:value>7570</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>615437</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>615437</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>AVEO Pharmaceuticals Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>053588109</ns1:cusip>
<ns1:value>190</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>52000</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>52000</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Axovant Sciences Ltd</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>G0750W104</ns1:cusip>
<ns1:value>275</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>40000</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:putCall>Call</ns1:putCall>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>40000</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>BioMarin Pharmaceutical Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>09061G101</ns1:cusip>
<ns1:value>11137</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>119661</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>119661</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Clovis Oncology Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>189464100</ns1:cusip>
<ns1:value>15218</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>184680</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>184680</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Clovis Oncology Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>189464100</ns1:cusip>
<ns1:value>2884</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>35000</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:putCall>Call</ns1:putCall>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>35000</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Cymabay Therapeutics Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>23257D103</ns1:cusip>
<ns1:value>121</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>15000</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>15000</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Dova Pharmaceuticals Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>25985T102</ns1:cusip>
<ns1:value>10638</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>438119</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>438119</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>FibroGen Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>31572Q808</ns1:cusip>
<ns1:value>11692</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>217329</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>217329</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Flexion Therapeutics Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>33938J106</ns1:cusip>
<ns1:value>6556</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>271136</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>271136</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>GlaxoSmithKline PLC</ns1:nameOfIssuer>
<ns1:titleOfClass>SPONSORED ADR</ns1:titleOfClass>
<ns1:cusip>37733W105</ns1:cusip>
<ns1:value>14537</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>358053</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>358053</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Global Blood Therapeutics Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>37890U108</ns1:cusip>
<ns1:value>8386</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>270075</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>270075</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>GlycoMimetics Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>38000Q102</ns1:cusip>
<ns1:value>4495</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>321286</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>321286</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Ignyta Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>451731103</ns1:cusip>
<ns1:value>3529</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>285728</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>285728</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Immunomedics Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>452907108</ns1:cusip>
<ns1:value>11074</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>792106</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>792106</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Impax Laboratories Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>45256B101</ns1:cusip>
<ns1:value>8169</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>402404</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>402404</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Insmed Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM PAR $.01</ns1:titleOfClass>
<ns1:cusip>457669307</ns1:cusip>
<ns1:value>4494</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>144000</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>144000</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Intec Pharma Ltd</ns1:nameOfIssuer>
<ns1:titleOfClass>SHS</ns1:titleOfClass>
<ns1:cusip>M53644106</ns1:cusip>
<ns1:value>2473</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>276324</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>276324</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Kura Oncology Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>50127T109</ns1:cusip>
<ns1:value>3865</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>258516</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>258516</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Madrigal Pharmaceuticals Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>558868105</ns1:cusip>
<ns1:value>1284</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>28536</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>28536</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Marinus Pharmaceuticals Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>56854Q101</ns1:cusip>
<ns1:value>3522</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>600000</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>600000</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Minerva Neurosciences Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>603380106</ns1:cusip>
<ns1:value>4080</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>536899</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>536899</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Paratek Pharmaceuticals Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>699374302</ns1:cusip>
<ns1:value>6082</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>242300</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>242300</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Sangamo Therapeutics Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>800677106</ns1:cusip>
<ns1:value>11715</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>781000</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>781000</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Seattle Genetics Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>812578102</ns1:cusip>
<ns1:value>20295</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>373000</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>373000</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Shire PLC</ns1:nameOfIssuer>
<ns1:titleOfClass>SPONSORED ADR</ns1:titleOfClass>
<ns1:cusip>82481R106</ns1:cusip>
<ns1:value>10666</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>69648</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>69648</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>SPDR S&P Biotech ETF</ns1:nameOfIssuer>
<ns1:titleOfClass>S&P BIOTECH</ns1:titleOfClass>
<ns1:cusip>78464A870</ns1:cusip>
<ns1:value>129855</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>1500000</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:putCall>Put</ns1:putCall>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>1000000</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>SteadyMed Ltd</ns1:nameOfIssuer>
<ns1:titleOfClass>SHS</ns1:titleOfClass>
<ns1:cusip>M84920103</ns1:cusip>
<ns1:value>867</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>258918</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>258918</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Supernus Pharmaceuticals Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>SHS NEW</ns1:titleOfClass>
<ns1:cusip>868459108</ns1:cusip>
<ns1:value>5291</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>132270</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>132270</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>TESARO Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>881569107</ns1:cusip>
<ns1:value>6455</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>50000</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:putCall>Put</ns1:putCall>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>50000</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Teva Pharmaceutical Industries</ns1:nameOfIssuer>
<ns1:titleOfClass>SPONSORED ADR</ns1:titleOfClass>
<ns1:cusip>881624209</ns1:cusip>
<ns1:value>17600</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>1000000</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:putCall>Put</ns1:putCall>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>1000000</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>VistaGen Therapeutics Inc</ns1:nameOfIssuer>
<ns1:titleOfClass>COM NEW</ns1:titleOfClass>
<ns1:cusip>92840H202</ns1:cusip>
<ns1:value>221</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>138132</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>138132</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
<ns1:infoTable>
<ns1:nameOfIssuer>Zosano Pharma Corp</ns1:nameOfIssuer>
<ns1:titleOfClass>COM</ns1:titleOfClass>
<ns1:cusip>98979H103</ns1:cusip>
<ns1:value>309</ns1:value>
<ns1:shrsOrPrnAmt>
<ns1:sshPrnamt>375809</ns1:sshPrnamt>
<ns1:sshPrnamtType>SH</ns1:sshPrnamtType>
</ns1:shrsOrPrnAmt>
<ns1:investmentDiscretion>SOLE</ns1:investmentDiscretion>
<ns1:votingAuthority>
<ns1:Sole>375809</ns1:Sole>
<ns1:Shared>0</ns1:Shared>
<ns1:None>0</ns1:None>
</ns1:votingAuthority>
</ns1:infoTable>
</ns1:informationTable>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>